SpliSense
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Hebrew University of Jerusalem Edmon...Phone Number
+972 528367731Website
www.splisense.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About SpliSense
Based in Jerusalem, Israel. SpliSense is a biopharmaceutical company focused on transformative mRNA-altering treatments targeting unmet needs in genetic pulmonary diseases. The company was founded in 2016.Explore more
SpliSense Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SpliSense your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
SpliSense, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if SpliSense had a recent Job posting/layoffs
Check if SpliSense has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on SpliSense recently announced quarterly report
Funding: Get notified immidiatlly once SpliSense has new funding data
Check out if SpliSense is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at SpliSense
Product Launch: Get notified when SpliSense launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
SpliSense is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SpliSense is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SpliSense.
SpliSense financials insights
Gather financial insights about SpliSense, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$28.5M
2026
Other Financing Round
$13M
SpliSense Tech Stack
A closer look at the technologies used by SpliSense
See more technologies
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
SpliSense News & Media
SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
e-PRIME recognition underscores potential of inhaled RNA therapy to address unmet need in patients with the 3849+10Kb C>T mutation Company advancing SPL84 to Phase 2b clinical study JERUSALEM, March 3, 2026 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing...SpliSense Receives FDA Fast Track Designation for SPL84 for the Treatment of Cystic Fibrosis
JERUSALEM, May 29, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma and NCFB and idiopathic pulmonary...SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis
- Funding secured from CF Foundation and current investors for SPL84 Phase 2 study - - Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company focused...SpliSense Successfully Completed Phase 1 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis
Phase 2 efficacy study to be initiated in H1 2024 New data published in Nucleic Acid Therapeutics demonstrate broad distribution, as well as cell and nucleus penetration of SPL84 in lungs of animal models, overcoming hyper-concentrated mucus barriers, thus leading to specific and targeted...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding SpliSense
Sign Up For FreeTo access detailed company insights
Based in Jerusalem, Israel. SpliSense is a biopharmaceutical company focused on transformative mRNA-altering treatments targeting unmet needs in genetic pulmonary diseases. The company was founded in 2016.... Read More
